BASEL, Switzerland, Sep 01, 2021 (GLOBE NEWSWIRE) – Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, will attend the Baird Global Healthcare 2021 conference on September 15, 2021 Company management will participate in a fireside chat at 2:35 p.m. EST, in addition to participating in small group investor meetings.
Investors and the general public are invited to listen to the Baird Fireside Chat, which will be accessible on the Events page under the heading Investors and media section of the Myovant website at www.myovant.com.
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and men through goal-driven science, empowering medicines and transformative advocacy. Founded in 2016, we have two products approved by FDA. ORGOVYX® (relugolix) was approved by the United States Food and Drug Administration in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist for the treatment of adult patients with advanced cancer of the prostate, and relugolix are also under regulatory review in Europe for men with advanced prostate cancer. The combined Relugolix tablet (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) was approved in 2021 in the United States as MYFEMBREE® as the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, and by the European Commission as RYEQO® for the treatment of moderate to severe symptoms of uterine fibroids in adult women of childbearing potential. The therapy has also completed phase 3 registration studies for women with endometriosis and is being evaluated for pregnancy prevention. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a phase 2a study on female infertility in assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. To follow @Myovant on Twitter and LinkedIn.
Vice-President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055